Cue Biopharma (CUE) Competitors $0.67 -0.04 (-5.34%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CUE vs. VYGR, YMAB, IVA, CRDF, PRME, INMB, TLSA, MOLN, ELDN, and CTMXShould you be buying Cue Biopharma stock or one of its competitors? The main competitors of Cue Biopharma include Voyager Therapeutics (VYGR), Y-mAbs Therapeutics (YMAB), Inventiva (IVA), Cardiff Oncology (CRDF), Prime Medicine (PRME), INmune Bio (INMB), Tiziana Life Sciences (TLSA), Molecular Partners (MOLN), Eledon Pharmaceuticals (ELDN), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical products" industry. Cue Biopharma vs. Voyager Therapeutics Y-mAbs Therapeutics Inventiva Cardiff Oncology Prime Medicine INmune Bio Tiziana Life Sciences Molecular Partners Eledon Pharmaceuticals CytomX Therapeutics Cue Biopharma (NASDAQ:CUE) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, community ranking, risk and profitability. Which has more risk & volatility, CUE or VYGR? Cue Biopharma has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Does the MarketBeat Community favor CUE or VYGR? Voyager Therapeutics received 255 more outperform votes than Cue Biopharma when rated by MarketBeat users. Likewise, 67.97% of users gave Voyager Therapeutics an outperform vote while only 52.33% of users gave Cue Biopharma an outperform vote. CompanyUnderperformOutperformCue BiopharmaOutperform Votes14652.33% Underperform Votes13347.67% Voyager TherapeuticsOutperform Votes40167.97% Underperform Votes18932.03% Is CUE or VYGR more profitable? Voyager Therapeutics has a net margin of 15.80% compared to Cue Biopharma's net margin of -468.02%. Voyager Therapeutics' return on equity of 8.33% beat Cue Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Cue Biopharma-468.02% -156.38% -88.07% Voyager Therapeutics 15.80%8.33%6.15% Which has higher valuation & earnings, CUE or VYGR? Voyager Therapeutics has higher revenue and earnings than Cue Biopharma. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCue Biopharma$7.99M6.31-$50.73M-$0.67-1.00Voyager Therapeutics$66.96M2.81$132.33M-$1.46-2.33 Does the media favor CUE or VYGR? In the previous week, Voyager Therapeutics had 7 more articles in the media than Cue Biopharma. MarketBeat recorded 7 mentions for Voyager Therapeutics and 0 mentions for Cue Biopharma. Voyager Therapeutics' average media sentiment score of 0.67 beat Cue Biopharma's score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Cue Biopharma Neutral Voyager Therapeutics Positive Do institutionals and insiders believe in CUE or VYGR? 35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 10.8% of Cue Biopharma shares are owned by insiders. Comparatively, 6.4% of Voyager Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts recommend CUE or VYGR? Cue Biopharma presently has a consensus target price of $3.00, indicating a potential upside of 348.03%. Voyager Therapeutics has a consensus target price of $13.39, indicating a potential upside of 293.82%. Given Cue Biopharma's higher probable upside, equities analysts plainly believe Cue Biopharma is more favorable than Voyager Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Voyager Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 SummaryVoyager Therapeutics beats Cue Biopharma on 14 of the 19 factors compared between the two stocks. Get Cue Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CUE vs. The Competition Export to ExcelMetricCue BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.45M$6.54B$5.43B$8.48BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-0.749.1426.7920.05Price / Sales6.31255.59394.72116.44Price / CashN/A65.8538.2534.62Price / Book0.826.546.864.61Net Income-$50.73M$143.51M$3.22B$248.19M7 Day Performance-10.13%5.60%6.83%2.97%1 Month Performance-14.29%10.06%13.73%16.58%1 Year Performance-64.48%-0.86%18.22%8.16% Cue Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CUECue Biopharma3.9469 of 5 stars$0.67-5.3%$3.00+348.0%-64.2%$50.45M$7.99M-0.7460VYGRVoyager Therapeutics4.6953 of 5 stars$3.35+5.7%$13.97+316.9%-59.8%$185.30M$80.00M4.72100Gap UpYMABY-mAbs Therapeutics3.5026 of 5 stars$4.07+4.6%$17.40+327.5%-64.2%$184.28M$87.69M-7.54150Analyst ForecastAnalyst RevisionIVAInventiva1.5076 of 5 stars$3.51-3.0%$10.40+196.3%-17.1%$184.19M$9.20M0.00100Gap DownCRDFCardiff Oncology1.5792 of 5 stars$2.75+3.4%$12.00+336.4%-13.3%$182.95M$683,000.00-2.9320Gap UpPRMEPrime Medicine3.767 of 5 stars$1.34+3.1%$13.14+880.8%-84.4%$175.76M$3.85M-0.65234Trending NewsAnalyst ForecastINMBINmune Bio1.9905 of 5 stars$7.64+9.6%$22.80+198.4%-31.6%$175.60M$14,000.00-3.5010Gap UpTLSATiziana Life Sciences1.0659 of 5 stars$1.50-4.5%N/A+94.8%$175.27MN/A0.008Gap UpMOLNMolecular Partners1.9779 of 5 stars$4.28+4.4%$12.00+180.4%+5.6%$172.81M$4.97M-1.99180News CoveragePositive NewsEarnings ReportAnalyst RevisionELDNEledon Pharmaceuticals2.1867 of 5 stars$2.87-0.7%$12.50+335.5%-1.9%$171.86MN/A-1.4310News CoveragePositive NewsEarnings ReportAnalyst RevisionGap UpCTMXCytomX Therapeutics4.2913 of 5 stars$2.13+129.4%$4.25+99.5%+7.3%$171.72M$138.10M12.53170Analyst RevisionHigh Trading Volume Related Companies and Tools Related Companies Voyager Therapeutics Alternatives Y-mAbs Therapeutics Alternatives Inventiva Alternatives Cardiff Oncology Alternatives Prime Medicine Alternatives INmune Bio Alternatives Tiziana Life Sciences Alternatives Molecular Partners Alternatives Eledon Pharmaceuticals Alternatives CytomX Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CUE) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
